There are no Transcripts on AXN.
Wed, Feb. 19, 3:43 PM
Oct. 16, 2012, 3:36 PMAoxing Pharmaceutical (AXN +7.4%) pops after the drug-maker reported a $15.9M net loss for FY12, but total revenue rose 22% year over year to $8.13M. The revenue gain was largely due to a 33% increase in sales of the company's main product, Zhongtongan, which is now being marketed for gynecological and orthopedic applications, in addition to its core dental market. Overall, Zhongtongan accounted for 89% of the company's FY12 sales. | Comment!
Sep. 13, 2012, 3:31 PM
AXN vs. ETF Alternatives
Other News & PR